TNFRSF1B and breast carcinoma: In TNFRSF1B, breast cancer patients who harbor the rs1061622 GT genotype had significantly reduced breast cancer risk compared with those harboring the TT genotype (P = 0.000662, OR = 0.706, 95% CI: 0.578–0.863 in Table 2).